Alto Neuroscience is a clinical-stage biopharmaceutical Company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. In January 2023, Alto reported positive results from a Phase 2b study in MDD ALTO-300 (agomelatine), an oral small molecule believed to act as a melatonin agonist. This signal was prospectively replicated to predict clinical response in an independent, locked, and blind